New drug combo explored for High-Risk blood cancer
NCT ID NCT04812548
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study tested a new drug called sabatolimab combined with two standard treatments (azacitidine and venetoclax) in 20 adults with high or very high risk myelodysplastic syndrome (MDS) who could not have intensive chemotherapy or a stem cell transplant. The goal was to see if the combination was safe and could help achieve complete remission, where signs of cancer disappear. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Brasschaat, 2930, Belgium
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Nice, 06202, France
-
Novartis Investigative Site
Düsseldorf, 40479, Germany
-
Novartis Investigative Site
Stuttgart, 70376, Germany
-
Novartis Investigative Site
Alexandroupoli, Evros, 681 00, Greece
-
Novartis Investigative Site
Pátrai, 265 00, Greece
-
Novartis Investigative Site
Nyíregyháza, 4400, Hungary
-
Novartis Investigative Site
Genova, GE, 16132, Italy
-
Novartis Investigative Site
Barcelona, Catalonia, 08036, Spain
Conditions
Explore the condition pages connected to this study.